**Author details**

Nika Kojc1 and Željka Večerić Haler2 \*

1 Institute of Pathology, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia

2 Department of Nephrology, University Medical Centre Ljubljana, Ljubljana, Slovenia

\*Address all correspondence to: zeljka.vecerichaler@kclj.si

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**87**

*Antibody Mediated Rejection in Kidney Transplant Recipients*

graft failure. American Journal of Transplantation. 2009;**9**(11):2532-2541

[9] Sypek M et al. HLA epitope

2018;**71**(5):720-731

2017;**28**(6):1912-1923

2014;**219**(2):109-112

2009;**87**(1):94-99

2011;**15**(1):E1-E7

2015. pp. 1352-1379

[11] Sapak M et al. Donor nonspecific MICA antibodies in renal transplant recipients. Immunobiology.

[12] Alvarez-Marquez A et al. Donorspecific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation.

[13] Narayan S et al. Acute rejection associated with donor-specific anti-MICA antibody in a highly sensitized pediatric renal transplant recipient. Pediatric Transplantation.

[14] Nickeleit V, Mengel M, Colvin RB. Renal transplant pathology. In: Jennete J, Olson J, Silva F, D'Agati V, editors. Heptinstall's Pathology of the Kidney. Philadelphia: Wolters Kluwer;

[15] Stegall MD, Chedid MF, Cornell LD. The role of complement in

[16] Haas M et al. The Banff 2017 kidney meeting report: Revised diagnostic criteria for chronic

antibody-mediated rejection in kidney transplantation. Nature Reviews. Nephrology. 2012;**8**(11):670-678

matching in kidney transplantation: An overview for the general nephrologist. American Journal of Kidney Diseases.

[10] Aubert O et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. Journal of the American Society of Nephrology.

*DOI: http://dx.doi.org/10.5772/intechopen.85886*

[1] Sellares J et al. Understanding the causes of kidney transplant failure: The dominant role of antibodymediated rejection and nonadherence. American Journal of Transplantation.

[2] Wan SS et al. The treatment of antibody-mediated rejection in kidney transplantation: An updated systematic review and meta-analysis. Transplantation. 2018;**102**(4):557-568

[3] Morozumi K et al. Reviewing the pathogenesis of antibody-mediated rejection and renal graft pathology after kidney transplantation. Nephrology.

[4] Loupy A, Lefaucheur C. Antibodymediated rejection of solid-organ allografts. The New England Journal of Medicine. 2018;**379**(12):1150-1160

[5] Kissmeyer-Nielsen F et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet. 1966;**2**(7465):662-665

[6] Adebiyi OO et al. Clinical significance of pretransplant donor-specific antibodies in the setting of negative cell-based flow cytometry crossmatching in kidney transplant recipients. American Journal of Transplantation. 2016;**16**(12):3458-3467

[7] McCaughan JA, Tinckam KJ. Donor specific HLA antibodies & allograft injury: Mechanisms, methods of detection, manifestations and

management. Transplant International.

[8] Hidalgo LG et al. De novo donorspecific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late

2018;**31**(10):1059-1070

2012;**12**(2):388-399

**References**

2016;**21**(Suppl 1):4-8

*Antibody Mediated Rejection in Kidney Transplant Recipients DOI: http://dx.doi.org/10.5772/intechopen.85886*
